University of Michigan School of Kinesiology

Ovarian Cancer: New Biological Markers Found That May Predict Which Patients Won't Respond to Chemotherapy

Retrieved on: 
torsdag, augusti 3, 2023
San Francisco, Doctor of Public Health, Mayo Clinic, University, University of Minnesota, Icahn School of Medicine at Mount Sinai, Neoplasm, University of Washington, Cohort (statistics), New York University Grossman School of Medicine, University of California, San Francisco, Baylor University, National Cancer Institute, Toxicity, MBA, Research, Mount Sinai, Doctor of Philosophy, University of Miami, Proteomics, MS, Amanda Paulovich, MD Anderson Cancer Center, University of Michigan School of Kinesiology, Death, Protein, Michigan Medicine, Patient, James D. Watson Institute of Genome Sciences, Baylor College of Medicine, University of Arkansas, Mortality, Trial of the century, Fred Hutchinson Cancer Research Center, Ovarian cancer, Dana–Farber Cancer Institute, Vaccine, Pharmaceutical industry, Medical imaging, Management, Genetics, MD, Cell, Medicine

NEW YORK, Aug. 3, 2023 /PRNewswire-PRWeb/ -- Using a novel proteogenomic strategy and a variety of machine learning tools, investigators from the Icahn School of Medicine at Mount Sinai and colleagues have identified a 64-protein signature that may predict a subset of ovarian cancer patients who are unlikely to respond to chemotherapy.

Key Points: 
  • The multicenter study, published online August 3 in Cell, reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC).
  • The multicenter study, published online August 3 in Cell [DOI#: 10.1016/j.cell.2023.07.004], reports on a pioneering analysis of chemo-refractoriness in high-grade serous ovarian cancer (HGSOC).
  • Currently, there's no way to distinguish refractory cases (who never respond to chemotherapy), leading some patients to unnecessarily experience the adverse effects of platinum-based chemotherapy without the benefits.
  • The investigators studied 242 tumors samples collected from HGSOC patients comprising both chemo-refractory and chemo-responsive individuals before they received chemotherapy.

Hail! Impact Adds Shelly Kovacs to Board; Increases Development Efforts as it Expands Transformative NIL Program to Multiple Sports

Retrieved on: 
onsdag, maj 24, 2023
University of Michigan School of Kinesiology, Curry School of Education, Letter, Football, Partnership, University, University of Michigan, Education, Life, ANN, PAG, Student Services, Woman, NIL (programming language), NIL, Organization, Athlete, Student, U of M, School, Haile Debas, Sport, Faculty, Growth, Ecosystem, Emory's Hope Clinic, Nursing, Management, Hail

The Shelly Kovacs Endowed Scholarship was created by UofM alumni in 2007 to honor her extraordinary accomplishments and thirty years of service to Michigan.

Key Points: 
  • The Shelly Kovacs Endowed Scholarship was created by UofM alumni in 2007 to honor her extraordinary accomplishments and thirty years of service to Michigan.
  • Ms. Kovacs joins Co-Founders Andrew Johnson and Chin Weerappuli and fellow director Michael Leach on Hail!
  • Mr. Johnson, Chairman of the Board, commented, “We are extremely honored to add Shelly Kovacs to the Hail!
  • NIL Program as a truly differentiated approach from all other NIL efforts across the country, built on meaningful charitable service and world-class educational engagements, is a game changer for Hail!

Curative Biotechnology, Inc. Announces Addition of Dr. Nicholas Boulis to Scientific and Clinical Advisory Board

Retrieved on: 
torsdag, september 2, 2021
Faculty, Research, Patient, OTC, Journal of Clinical Neuroscience, Journal, Neurology, Clinical, Review, Heart, Securities Act of 1933, Neuroprotection, Emory University School of Medicine, Philosophy, Harvard Medical School, CD56, Cleveland, Biological engineering, University of Michigan School of Kinesiology, Cleveland Clinic, Securities Exchange Act of 1934, Company, OTC Markets Group, Experimental Neurology, Emory School, Biology, University, Cell, Judgement, Deep brain stimulation, Michael, GLOBE, Coronavirus Scientific Advisory Board (Turkey), Disease, Gene, Yale University, Medical device

Boca Raton, FL, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT), announced today the addition of Dr. Nicholas Boulis, MD/PhD to the company's Scientific and Clinical Advisory Board. Dr. Boulis is on the faculty of the Emory School of Medicine in Atlanta and is the Director of Emory University's Gene and Cell Therapy for Neurorestoration Laboratory.

Key Points: 
  • Boca Raton, FL, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT), announced today the addition of Dr. Nicholas Boulis, MD/PhDto the company's Scientific and Clinical Advisory Board.
  • Dr. Boulis has been on the faculty at The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and at the University of Michigan School of Medicine.
  • Dr. Boulis serves on the Michael J Fox Foundation Advisory Committee on Deep Brain Stimulation Research.
  • Paul Michaels, Chairman and President of Curative Biotech, said, "We are extremely pleased with the addition of Dr. Boulis to the Clinical and Scientific Advisory Board.